DexCompress Q1 Earnings Beat Expectations, 2026 Guidance Raised
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy DXCM?
Source: seekingalpha
- Strong Earnings Report: DexCompress reported a Q1 Non-GAAP EPS of $0.56, beating expectations by $0.09, which reflects the company's ongoing profitability enhancement and reinforces market confidence in its future performance.
- Revenue Growth: The company achieved Q1 revenue of $1.19 billion, representing a 14.4% year-over-year increase and exceeding market expectations by $20 million, indicating robust demand and product acceptance in the market.
- 2026 Guidance Raised: DexCompress has raised its fiscal year 2026 revenue guidance to between $5.16 billion and $5.25 billion, projecting approximately 11-13% growth, while reiterating its Non-GAAP Gross Profit Margin and Operating Margin guidance, showcasing confidence in future growth.
- Margin Outlook: The company anticipates a Non-GAAP Gross Profit Margin of approximately 63-64%, a Non-GAAP Operating Margin of around 23-23.5%, and an Adjusted EBITDA Margin of approximately 31-31.5%, which will further enhance investor appeal and confidence in its financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise
16 Analyst Rating
13 Buy
2 Hold
1 Sell
Strong Buy
Current: 60.910
Low
68.00
Averages
82.54
High
100.00
Current: 60.910
Low
68.00
Averages
82.54
High
100.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DexCom Reports 15% Revenue Growth in Q1 2026
- Significant Revenue Growth: DexCom reported Q1 2026 revenue of $1.192 billion, reflecting a 15% year-over-year increase, driven by an 11% rise in U.S. revenue and a remarkable 26% surge in international sales, indicating strong global market performance.
- Margin Expansion: The company achieved a GAAP operating income of $255.3 million, representing 21.4% of revenue, which marks an 850 basis point improvement compared to Q1 2025, showcasing successful cost control and operational efficiency.
- Product Innovation Advancement: The expanded launch of the Dexcom G7 15-day CGM system and enhanced features for the Stelo platform further solidify DexCom's market position in real-time health management, catering to the growing user demand.
- Full-Year Performance Outlook: DexCom raised its full-year 2026 guidance for non-GAAP operating margin and adjusted EBITDA margin to 23% to 23.5% and 31% to 31.5%, respectively, while maintaining its annual revenue forecast of $5.16 billion to $5.25 billion, reflecting confidence in future growth.
See More
Investigation into DexCom Shareholder Rights
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties, potentially leading to shareholder losses.
- Legal Fee Arrangement: The firm promises to handle cases on a contingent fee basis, meaning shareholders will not incur upfront legal costs, thus reducing the financial burden of participation.
- Importance of Participation: Shareholder involvement can help improve company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately boosts shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on implementing corporate reforms and recovering millions for defrauded investors, showcasing its expertise in protecting investor rights.
See More
DexCom Announces Investor Day on May 14, 2026
- Investor Day Announcement: DexCom will host its Investor Day on May 14, 2026, from 1:15 PM to 3:30 PM PDT, where management will discuss market opportunities, business strategy, innovation efforts, and long-term financial outlook.
- Live Webcast Availability: The event will feature a live webcast accessible via the DexCom Investor Relations website, ensuring that all stakeholders can stay informed about the company's latest developments in real-time.
- Company Background: Founded in 1999, DexCom has pioneered glucose biosensing technology for over 25 years, focusing on empowering individuals to manage diabetes through innovative solutions.
- Technological Impact: DexCom's technology has transformed diabetes management and glucose tracking, enabling users to take control of their health and live more confidently, showcasing the company's leadership in the health tech sector.
See More
Atlassian and Others See Significant Stock Gains
- Atlassian's Optimistic Guidance: Atlassian shares surged 23% after projecting a 24% revenue growth for the year, exceeding its previous 22% forecast and the FactSet consensus of 22.2%, indicating strong market performance and growth potential.
- nVent Electric's Strong Earnings: nVent's stock jumped 11% as first-quarter EPS and revenue surpassed Wall Street's highest estimates, with full-year revenue growth forecasted at 26% to 28%, significantly above the consensus of 18%, reflecting robust demand in data centers and energy storage.
- Cboe Global Markets Layoffs: Cboe shares rose 9% following the announcement of a 20% workforce reduction, with first-quarter adjusted EPS at $3.70 and revenue of $728.9 million, both exceeding market expectations, demonstrating the company's commitment to operational optimization.
- Roku's Revenue Beat: Roku's stock increased by 4% after reporting first-quarter revenue of $1.25 billion, surpassing the expected $1.20 billion, with adjusted EBITDA also exceeding estimates, showcasing the company's ongoing growth potential in the streaming market.
See More
DEXCOM STOCK RECOVERS IN PREMARKET TRADING, RISING 4.3% FOLLOWING Q1 RESULTS
- Stock Performance: Dexcom shares have reversed their pre-market decline, increasing by 4.3% following the release of Q1 results.
- Market Reaction: The positive movement in Dexcom's stock indicates investor confidence after the company's quarterly performance report.
See More
Apple, Roku, Estée Lauder Beat Earnings Expectations
- Apple's Strong Earnings: Apple reported a fiscal second-quarter earnings of $2.01 per share and revenue of $111.18 billion, surpassing analyst expectations of $1.95 and $109.66 billion, although iPhone sales missed estimates for the third consecutive quarter, indicating increasing market competition pressures.
- Roku's Robust Growth: Roku's first-quarter revenue reached $1.25 billion, exceeding the expected $1.20 billion, with adjusted EBITDA of $148.4 million also above the forecast of $131.3 million, highlighting the company's ongoing growth potential in the streaming market.
- Estée Lauder's Better-Than-Expected Performance: Estée Lauder reported third-quarter earnings of $0.91 per share and revenue of $3.71 billion, both exceeding analyst estimates, despite announcing job cuts as part of its turnaround strategy, reflecting its adaptive measures in a changing market.
- Moderna's Improved Financials: Moderna posted a first-quarter loss of $3.40 per share, better than the anticipated loss of $4.45, with revenues of $389 million surpassing the $236.4 million estimate, indicating its sustained competitiveness in the vaccine market.
See More
DexCom Reports 15% Revenue Growth in Q1 2026
- Significant Revenue Growth: DexCom reported Q1 2026 revenue of $1.192 billion, reflecting a 15% year-over-year increase, driven by an 11% rise in U.S. revenue and a remarkable 26% surge in international sales, indicating strong global market performance.
- Margin Expansion: The company achieved a GAAP operating income of $255.3 million, representing 21.4% of revenue, which marks an 850 basis point improvement compared to Q1 2025, showcasing successful cost control and operational efficiency.
- Product Innovation Advancement: The expanded launch of the Dexcom G7 15-day CGM system and enhanced features for the Stelo platform further solidify DexCom's market position in real-time health management, catering to the growing user demand.
- Full-Year Performance Outlook: DexCom raised its full-year 2026 guidance for non-GAAP operating margin and adjusted EBITDA margin to 23% to 23.5% and 31% to 31.5%, respectively, while maintaining its annual revenue forecast of $5.16 billion to $5.25 billion, reflecting confidence in future growth.
See More
Investigation into DexCom Shareholder Rights
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties, potentially leading to shareholder losses.
- Legal Fee Arrangement: The firm promises to handle cases on a contingent fee basis, meaning shareholders will not incur upfront legal costs, thus reducing the financial burden of participation.
- Importance of Participation: Shareholder involvement can help improve company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately boosts shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on implementing corporate reforms and recovering millions for defrauded investors, showcasing its expertise in protecting investor rights.
See More
DexCom Announces Investor Day on May 14, 2026
- Investor Day Announcement: DexCom will host its Investor Day on May 14, 2026, from 1:15 PM to 3:30 PM PDT, where management will discuss market opportunities, business strategy, innovation efforts, and long-term financial outlook.
- Live Webcast Availability: The event will feature a live webcast accessible via the DexCom Investor Relations website, ensuring that all stakeholders can stay informed about the company's latest developments in real-time.
- Company Background: Founded in 1999, DexCom has pioneered glucose biosensing technology for over 25 years, focusing on empowering individuals to manage diabetes through innovative solutions.
- Technological Impact: DexCom's technology has transformed diabetes management and glucose tracking, enabling users to take control of their health and live more confidently, showcasing the company's leadership in the health tech sector.
See More
Atlassian and Others See Significant Stock Gains
- Atlassian's Optimistic Guidance: Atlassian shares surged 23% after projecting a 24% revenue growth for the year, exceeding its previous 22% forecast and the FactSet consensus of 22.2%, indicating strong market performance and growth potential.
- nVent Electric's Strong Earnings: nVent's stock jumped 11% as first-quarter EPS and revenue surpassed Wall Street's highest estimates, with full-year revenue growth forecasted at 26% to 28%, significantly above the consensus of 18%, reflecting robust demand in data centers and energy storage.
- Cboe Global Markets Layoffs: Cboe shares rose 9% following the announcement of a 20% workforce reduction, with first-quarter adjusted EPS at $3.70 and revenue of $728.9 million, both exceeding market expectations, demonstrating the company's commitment to operational optimization.
- Roku's Revenue Beat: Roku's stock increased by 4% after reporting first-quarter revenue of $1.25 billion, surpassing the expected $1.20 billion, with adjusted EBITDA also exceeding estimates, showcasing the company's ongoing growth potential in the streaming market.
See More
DEXCOM STOCK RECOVERS IN PREMARKET TRADING, RISING 4.3% FOLLOWING Q1 RESULTS
- Stock Performance: Dexcom shares have reversed their pre-market decline, increasing by 4.3% following the release of Q1 results.
- Market Reaction: The positive movement in Dexcom's stock indicates investor confidence after the company's quarterly performance report.
See More
Apple, Roku, Estée Lauder Beat Earnings Expectations
- Apple's Strong Earnings: Apple reported a fiscal second-quarter earnings of $2.01 per share and revenue of $111.18 billion, surpassing analyst expectations of $1.95 and $109.66 billion, although iPhone sales missed estimates for the third consecutive quarter, indicating increasing market competition pressures.
- Roku's Robust Growth: Roku's first-quarter revenue reached $1.25 billion, exceeding the expected $1.20 billion, with adjusted EBITDA of $148.4 million also above the forecast of $131.3 million, highlighting the company's ongoing growth potential in the streaming market.
- Estée Lauder's Better-Than-Expected Performance: Estée Lauder reported third-quarter earnings of $0.91 per share and revenue of $3.71 billion, both exceeding analyst estimates, despite announcing job cuts as part of its turnaround strategy, reflecting its adaptive measures in a changing market.
- Moderna's Improved Financials: Moderna posted a first-quarter loss of $3.40 per share, better than the anticipated loss of $4.45, with revenues of $389 million surpassing the $236.4 million estimate, indicating its sustained competitiveness in the vaccine market.
See More
